Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
COMMUNICATION DISORDERS IN THE MALTESE CHILD POPULATION (CDMCP)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Intra-European Fellowships
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Ireland
Call:  (FP7-PEOPLE-IEF-2008, 2008)
Start date: 2010-03-01
End date: 2011-03-31
Duration (months): 13.0
Total project cost (EUR): 65444.03
EU funding (EUR): 65444.03
Participants: 1
Project status: CLOSED

The primary purpose of the proposed fellowship is to provide the opportunity to standardize speech and language assessments that can identify monolingual and bilingual Maltese children who have speech and language impairment. Such children are at risk of disadvantage socially and academically unless identified and therapy is provided. Research on English-speaking populations suggests that approximately 10% of all children have difficulties acquiring speech and/or language in the absence of other impairments However, no data are available for bilingual populations or countries (such as Malta) where most of the population speaks more than language. The objectives of the study are: -To compare and contrast monolingual (Maltese or English) and bilingual (Maltese and English) language development in the bilingual language learning context of Malta; -To establish normative data for four novel assessments, for monolingual and bilingual children aged 2;0-6;0, for receptive and expressive language; -To prepare the assessments for clinical use by speech-language therapists to identify children with delayed or disordered language acquisition who come from monolingual or bilingual home environments; -To describe the characteristics of different types of functional developmental language disorders (receptive and expressive) in the Maltese language; -To analyze data from Maltese children with speech disorder to validate an assessment of articulation and phonology for which normative data are already established (Grech and Dodd, 2008); -To determine factors affecting choice of language code (language switching/mixing and use of translation equivalents). Language samples already collected from large groups of typically developing (N = 241) and language disordered (N = 150) 2-6 year old Maltese children, will be analyzed. This is a follow-up study of a project funded by the Marie Curie Transfer of Knowledge Scheme (Contract No: MTKD-CT-2004-509833).

Keywords: health sciences,communication disorders,speech & language therapy,bilingual language acquisition & impairment
The Impact of Climate Change on the Southeast Asian Monsoon (ASIAN MONSOON)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Intra-European Fellowships
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: United Kingdom
Call:  (FP7-PEOPLE-IEF-2008, 2008)
Start date: 2009-05-01
End date: 2011-04-30
Duration (months): 24.0
Total project cost (EUR): 183618.8
EU funding (EUR): 183618.8
Participants: 1
Project status: CLOSED

Changes in Asian monsoon variability can affect more than 50% of the world population, yet our understanding of the monsoon is incomplete. The proposed research will bring new insight into this crucial component of the Earth’s climate system while using world-class equipment and resources available at the host institution, the University of Oxford. This research will contribute to a deeper understanding of a critical but understudied portion of the Asian monsoon, the Southeast Asian monsoon, by producing a high-quality climate reconstruction using speleothems (cave carbonate formations) from Laos. Speleothems are widely considered as one of the best climate archives available. They can be precisely dated and their geochemical composition preserves long and detailed information of past climate change. I will capitalize on these properties of speleothems to address key questions regarding past variability of the Southeast Asian monsoon: (1) What is the long-term history of the Southeast Asian monsoon, and how does this compare to records from the South and East Asian monsoons? (2) Are recent changes in the relationship between El Nino and the monsoon a response to global warming? (3) Are changes in Southeast Asian monsoon strength driven from the northern or southern hemisphere? (4) Can comparison of oxygen isotope records along moisture transport pathways provide quantification of past rainfall? The societal and economic implications of climate change ensure that understanding the behavior of the climate system will continue to attract widespread research, together with public, economic, and government interest, for decades to come. Moreover, an understanding of the mechanisms of climate change that impact the Asian monsoon region, as proposed here, is essential for scientists and policy makers in the European Union and worldwide because climate variations are known to influence key natural resources and are associated with regional hazards and disasters.

Keywords: paleoclimate (climate change),monsoon,enso,speleothems,southeast asia,laos
A state-of-the-art pulsar survey to aid gravitational wave detection efforts through pulsar timing (PULSAR SURVEY)

Framework: FP7 — People
Programme: Marie-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Intra-European Fellowships
Action type: Support for training and career development of researchers (Marie Curie)
Countries involved: Germany
Call:  (FP7-PEOPLE-IEF-2008, 2008)
Start date: 2010-03-01
End date: 2012-02-29
Duration (months): 24.0
Total project cost (EUR): 165532.99
EU funding (EUR): 165532.99
Participants: 1
Project status: CLOSED

We propose to undertake the first state-of-the-art, all-sky survey for pulsars in the Northern sky since long. The main aim is to discover highly stable pulsars with milli-second periods, which can be used in a so-called &quot;pulsar timing array&quot; to make the first direct detection of gravitational waves. The recent technological developments at the Effelsberg telescope near Bonn (Germany) are expected to make the survey speed much higher and the sensitivity to the most rapidly rotating pulsars far better than any previous all-sky survey undertaken in the North. The expected discoveries will boost pulsar research in Europe and strengthen Europe&apos;s involvement in the global efforts at gravitational wave detection. Concurrently, we plan to optimise the observing strategy for the European pulsar timing array through multi-frequency investigations of the current source list and through optimisation of that source list with new discoveries.

Keywords: astrophysics,relativity,pulsars,interstellar medium,gravitational waves
Identifying and validating pre-clinical biomarkers for diagnostics and therapeutics of Neuromuscular Disorders (BIO-NMD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Italy,Netherlands,United Kingdom,United Kingdom,France,Sweden,Germany,France,France,Germany,United States
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-12-01
End date: 2012-11-30
Duration (months): 36.0
Total project cost (EUR): 7539671.4
EU funding (EUR): 5634356.0
Participants: 15
Project status: CLOSED

The rapidly expanding knowledge of NMDs genetic diagnosis, pathogenesis and therapeutic possibilities has provided new targets for disease characterisation, early diagnosis, drug discovery and development as well as has raised many questions about how to translate this knowledge into clinical practice as (initial) clinical trials typically run for such a short time that clinical improvement can hardly be expected within that time frame. This militates for the discovery of surrogate endpoints for establishing the efficacy of clinical trials. The concept of biomarkers represents measurable bio-parameters able to flank the process of diagnosis, functional characterisation and therapy in NMDs. OMIC sciences (genomic, transcriptomics, proteomics) offer opportunities to identify biomarkers for finely defining and tuning the NMDs bases. This approach can make available non-invasive biomarkers, to be used for monitoring disease progression, prognosis and drugs response, therefore optimising the choice of appropriate and often personalised therapies. Validated biomarkers will increase therapy efficiency (meaning optimal dose of drug to get responders) and efficacy (responders vs non responders for example if we will identify genomic biomarkers linked to the lack of any therapeutic effect). In this case we could address a truly efficacious therapy (avoiding inefficacious treatment due to unfavourable genomic contexts). The new genomic and proteomic biomarkers discovered within BIO-NMD will be validated both in animal models and in human samples, before entering into a qualification process at the EMEA. The qualified biomarkers resulting from the BIO-NMD project will be ready for ongoing and further clinical trials for the patient benefit. This will increase the therapy efficacy and efficiency and also reduce adverse effects, with impact on patients’ quality of life with also economical relevance. The BIO-NMD consortium is led by the University of Ferrara, an internationally recognised university in the field of genomics of hereditary neuromuscular disorders. In addition the consortium is composed of 7 leading European academic partners bringing their expertise in all OMIC sciences as well as in bio-informatics and patient sample collection, 1 SME providing its skills in bio-informatics and 1 global company specialised in the development of patient samples screening.

Keywords: neuromuscular disorders,genomic biomarkers,proteomic biomarkers,bioinformatics,ethics,diagnosis,treatment,pathophysiology,prognosis
Arrhythmogenic potential of drugs (ARITMO)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Netherlands,Spain,United Kingdom,Italy,Germany,United Kingdom,France,Italy,Germany,Sweden,Denmark,Netherlands,Netherlands
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2013-06-30
Duration (months): 42.0
Total project cost (EUR): 3616797.44
EU funding (EUR): 2748319.0
Participants: 20
Project status: CLOSED

The ability of some compounds to prolong the QT interval of the electrocardiogram and to precipitate Torsade de Pointes (TdP, a potentially fatal arrhythmia) has caused several regulatory interventions, including drug withdrawals. Specific guidelines have been implemented to detect QT liability of new compounds as early as possible. However there is growing evidence that an increase in the QT interval does not necessarily lead to TdP which further increased the regulatory and clinical difficulties. This proposal will assess the arrhythmogenic potential of antipsychotics, antihistamines and anti-infectives (&gt; 250 compounds). It will fulfill this aim by: reviewing the literature on in-vitro and in-vivo preclinical evidence; conducting in-silico modeling to predict the arrhythmic potential through target profiling and docking molecules in existing atomistic models and predicting the effects on hERG K+, Na+, Ca++ channels; analyzing the information in national and international pharmacovigilance DBs of spontaneous reports; conducting prospective case control surveillance on symptomatic QT prolongation; conducting cohort studies in psychiatric and hematology patients; analyzing information from existing studies to assess the association between drug use and various arrhythmia outcomes; and collecting blood samples from cases and drug-matched controls to investigate potential effect modification by candidate genes and a hypothesis generating approach including more than 2000 genes. Healthcare DBs on 27 million persons in 5 countries will be used to calculate rates and relative risks of arrhythmic events during drug use. Predictions on arrhythmic potential will be compared with actual postmarketing risk to assess the predictive value of preclinical markers. All information will be integrated to allow for ranking the arrhythmic potential of all the 250 study drugs and creation of risk charts that will allow for more informed treatment and decision making.

Keywords: qt-liability,antihistaminics,anti-infectives,antipsychotics,arrhythmia
EUROpean multilevel integrated BIOREFinery design for sustainable biomass processing (EUROBIOREF)

Framework: FP7 — Cooperation
Programme: Energy
Destination: Renewable fuel production
Action type: Collaborative project
Countries involved: France,France,Denmark,France,Greece,Switzerland,Belgium,Denmark,Germany,Germany,Portugal,Germany,Italy,Poland,Norway,Germany,United Kingdom,France,Poland,Germany,Netherlands,Poland,Madagascar,Sweden,Bulgaria,Belgium
Call:  (FP7-2009-BIOREFINERY_CP, 2009)
Start date: 2010-03-01
End date: 2014-02-28
Duration (months): 48.0
Total project cost (EUR): 36648416.26
EU funding (EUR): 23073794.0
Participants: 34
Project status: CLOSED

The development and implementation of bio-refinery processes is an absolute necessity and the key to meet the vision towards bio-based economy. The EuroBioRef concept is an integrated, sustainable and diversified bio-refinery involving all biomass value chain stakeholders. The latter will allow large-scale research, testing, optimisation and demonstration of processes in the production of a wide range of products with the dual aim to use all fractions of various biomasses and exploit their potential to produce the highest value possible in an eco-efficient and sustainable way. Moreover, the project attempts to overcome the efforts fragmentation of the whole biomass value chain requiring greater networking, coordination and cooperation among a large variety of actors from biochemical and chemical industry, SMEs, scientific knowledge chain, and European organisations. The new concept will adopt a flexible and a modular process design adapted to large- but also small-scale production units easier to install in various European areas. The overall efficiency of this approach will clearly exceed existing pathways and will consider sustainable options in order to: - Produce and use a high diversity of sustainable biomasses adapted for European regions - Produce high specific energy bio-jet fuels (42 MJ/kg) - Produce multiple products (chemicals, polymers, materials) in a flexible and optimised way that take advantage of the differences in biomass components and intermediates - Improve cost-efficiency by 30% through improved reaction and separation effectiveness, reduced capital investments, improved plant and feedstock flexibility, reduction of production time and logistics - Reduce by 30% the energy - Produce zero waste and rationalise use of raw materials The impact of the project in terms of environment, social and economic benefits is important and could give a serious advantage for European bio-industry.

Keywords: biomass,biorefinery,catalysis,biochemical and chemical conversion,bio-jet fuels
ADIPOSE DERIVED STROMAL CELLS FOR OSTEOARTHRITIS (ADIPOA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,Ireland,France,Italy,France,Netherlands,Germany,France,Germany,Lithuania,Israel
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-06-30
Duration (months): 54.0
Total project cost (EUR): 12083457.0
EU funding (EUR): 9224472.0
Participants: 12
Project status: CLOSED

Osteoarthritis (OA) is a degenerative joint disease for which no efficient therapy is available. The ADIPOA consortium has previously shown that intraarticular injections of stromal cells prevents OA in two different models, but the mechanisms of this chondroprotective effect remains unknown, and the activation of cartilage derived endogenous stem cells is suspected. The participants have experience on cell therapy, logistic and production facilities for adipose derived stromal cells (ASC) and clinical studies focusing on cartilage repair. They have shown that stromal cells have anti-inflammatory and antiapoptosis effets, prevent cells from senescence and protect endogenous cells from oxidative stress. ASC are well described, and the procedure to expand the ASC in GMP clinical grade by one of us has been approved by regulatory authorities. This has prompted us to propose an original and innovative regenerative medicine approach for OA in a four years programme organised around 6 workpackages : · WP 1 ASC biology, cell processing &amp; optimization for chondral protection · WP 2 In vivo validation of chondroprotective effect of ASC · WP 3 Safety, Security &amp; regulatory issues · WP 4 Clinical trial endogenous ASC injected intraarticular in OA · WP 5 Management and Coordination · WP 6 Training and Education ADIPOA project will then lead to the optimisation and standardisation of production procedures. In vivo validation and optimisation shall lead to a phase 1 clinical trial and the design and initiation of a phase 2 controlled study in OA. The ADIPOA Consortium comprises 10 academic and 2 sme participants and gathers researchers and clinicians with expertise in clinical research, chondrocytes and adipose stem cell biology and regenerative medicine. The Sme participation will ensure the dissemination of the project results. The critical mass achieved by the ADIPOA Consortium should enable clinical applications in OA.

Keywords: stem cells,chondrocytes,healthy aging,osteoarthritis
EuroHOPE – European Health Care Outcomes, Performance and Efficiency (EUROHOPE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Finland,Italy,Hungary,Netherlands,Norway,United Kingdom,Sweden
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-04-30
Duration (months): 52.0
Total project cost (EUR): 3948070.67
EU funding (EUR): 2995318.0
Participants: 8
Project status: CLOSED

By using available databases as well as by collecting additional data on health-related quality of life measures (enabling Quality Adjusted Life Years as an outcome measure) and patient satisfaction (including expectations) the EuroHOPE project will evaluate, through a microeconomic disease-based approach, the performance of European health care systems in terms of outcomes, quality, use of resources and cost. Concentration will be on five important health problems/diseases: acute myocardial infarction, stroke, hip fracture, breast-cancer, and very low birth weight infants. The project has the following specific aims and objectives: (i) develop methods to measure outcomes and costs of care of specific diseases that can be used for routine evaluation of care given in the whole cycle of care (not only for specific procedures or short episodes); (ii) develop methods to measure quality, access, outcomes and cost of (care) that can be used for routine evaluation and monitoring of the performance, and give a recommendation of a list of indicators to be routinely collected and published by the EU (as a part European community Health Indicators); (iii) develop methods for international comparative health service research using register data; (iv) investigate the relationship between outcomes (or quality) with costs (or other measures of use of resources) between European countries, regions and providers applying a multilevel approach; (v) explore reasons behind difference in outcomes and costs. In particular, the interest will be on policy driven factors (such as treatment practices, use of medicines and modern technology, waiting times, financing, organisation of delivery, and reforms); (vi) give proposals concerning the data content of national level registers and outcome measurements in order to improve the continuous monitoring of performance on an intra- and international level; and (vii) implementing European-wide benchmarking on outcomes, quality and costs, which ena

Keywords: health care,performance,efficiency,outcome,disease-based approach,europe
Marine Water Quality Information Services – AquaMar (AQUAMAR)

Framework: FP7 — Cooperation
Programme: Space
Destination: Space-based applications at the service of the European Society
Action type: Collaborative project
Countries involved: France,France,Germany,Italy,Denmark,Belgium,Finland,United Kingdom,Spain,Denmark,Germany,United Kingdom,Netherlands,Norway,United Kingdom
Call:  (FP7-SPACE-2009-1, 2009)
Start date: 2010-04-01
End date: 2013-03-31
Duration (months): 36.0
Total project cost (EUR): 4875594.89
EU funding (EUR): 3499742.5
Participants: 17
Project status: CLOSED

Water quality (WQ) is a focus of monitoring agencies and the public, and it is subject of several European Directives and regional conventions. The AquaMar project will develop and provide downstream services turning Marine Core Service products into WQ services, demanded by end user. The team is composed mainly of SMEs (70%) supported by key scientific partners. The objective is to create a reference technical and organisational body at European level for WQ services, organised as an open partnership, through: · methodological research extending traditional WQ portfolio along 5 novel product lines · turning these into pre-operational services, including adaptation to MCS · establishing a validation &amp; quality evolution process and data model · evaluate the services with end users through service delivery trials · transferring the developed services to other services providers (SP) through a well defined process (technical and organisational framework). The service portfolio includes (1) indicators for the reporting requirement of the Water Framework Directive and the European Marine Strategy, (2) algal bloom forecasting, (3) support to large scale marine infra., (4) services supporting the Bathing Water directive monitoring, (5) aquaculture precision farming. This is complemented by research on methods for improved standard WQ products, geostatistics, and distribution tech., to be used across the service portfolio. In parallel, a validation and quality evolution strategy is developed and applied, including the services sustainability wrt new space sensors. A user &amp; customer board is steering the project, participating in the trials and providing feedback to the MCS, the validation and research activities. The aim is to prepare the ground for a sustainable continuation and growth of WQ services, starting from heritage of 3 GSE projects (CoastWatch, ROSES, MarCoast) comprising a baseline portfolio of standard WQ products, a European wide user base and SP networ

Keywords: water quality,downstream services,gmes